First in human study with ODM-207 in patients with selected advanced cancers to assess its safety and how the body affects it

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004826-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Part 1: To evaluate the safety and tolerability, define the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) if possible, and define the recommended doses and dosing schedules of ODM-207 for Part 2 of the study. Part 2: To further evaluate the safety and tolerability, and preliminary antitumour activity of ODM-207 at the dose levels recommended for further clinical studies in patient populations with selected tumour types.


Critère d'inclusion

  • Advanced Solid Tumours

Liens